Bill
HB 2584
Prohibits health plans and Medicaid from requiring prior authorization for HIV PrEP/PEP and HIV treatment drugs (and equivalents), speeding access.
Status snapshot
- Introduced: February 2025 (Rep. Kelly M. Cassidy, primary sponsor)
- House passage: Passed (vote recorded April 11, 2025; House amendments adopted)
- Sent to Senate: Arrived April 14, 2025; referred to Senate committees and reassigned to Appropriations – Health & Human Services
- Effective date (if enacted): January 1, 2027
- Companion bill: SB 1145
Purpose
- To remove prior‑authorization barriers for key HIV medicines by prohibiting health plans and Medicaid programs from requiring prior authorization for HIV pre‑exposure prophylaxis (PrEP), post‑exposure prophylaxis (PEP), and HIV treatment drugs (and their FDA‑approved therapeutic equivalents).
Key provisions
- Adds a new Section to the Prior Authorization Reform Act (215 ILCS 200/52 new):
- Prohibits health insurance issuers from requiring prior authorization for:
- Human immunodeficiency virus (HIV) pre‑exposure prophylaxis (PrEP) and post‑exposure prophylaxis (PEP) medications, and
- HIV treatment medications,
- including their therapeutic (FDA‑recognized) equivalents.
- Adds a new Section to the Illinois Public Aid Code (305 ILCS 5/5‑54 new):
- Prohibits the fee‑for‑service Medicaid program and Medicaid managed care organizations from requiring prior authorization for the same categories of HIV medications and therapeutic equivalents.
- The bill defines “therapeutic equivalent version” consistent with FDA standards (pharmaceutical equivalence, bioequivalence, labeling, manufacturing quality).
- Other insurance‑code language in the bill package addresses coverage rules for abortifacients and related conditions (provider deference, formulary and cost‑sharing conditions); much of that language amends existing Section 356z.60, but the prior‑authorization prohibition is the principal targeted change in the Prior Authorization Reform Act and Public Aid Code.
Who is affected
- Patients: People seeking PrEP, PEP, or HIV treatment medications (commercially insured and Medicaid enrollees) — the bill aims to reduce administrative delays and improve timely access to these drugs.
- Payers: Private health insurance issuers, fee‑for‑service Medicaid program, and Medicaid managed care organizations — they would be prohibited from imposing prior authorization requirements for the specified drug categories.
- Providers and pharmacies: Clinical prescribers and dispensing pharmacies may see operational changes (fewer prior‑authorization workflows and appeals).
- State budget/administration: Medicaid drug spending and program administration may be affected; fiscal and budget notes were filed as part of committee processes.
Potential impacts and considerations
- Access/clinical: Removing prior authorization can speed initiation and continuity of PrEP/PEP and ART, supporting prevention and treatment goals and potentially reducing HIV transmission and complications.
- Fiscal: Short‑term pharmacy spending in Medicaid and commercial plans could increase if utilization rises; long‑term health system savings are possible if HIV incidence and complications decline. Exact fiscal impact would depend on utilization changes and offsets and is informed by committee fiscal notes.
- Implementation: Effective January 1, 2027, if enacted. The bill prohibits prior authorization but does not itself mandate specific coverage levels, quantity limits, or cost‑sharing structures beyond other applicable insurance or Medicaid rules.
Legislative process notes
- The bill passed the Illinois House with amendments and generated multiple committee actions, amendments, and accompanying insurance‑code changes (including broader reproductive and coverage provisions). It has numerous co‑sponsors and a Senate companion (SB 1145); final outcome depends on remaining Senate committees and floor action.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
